Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

hyperpolarized carbon 13 alpha-ketoglutarate

A radioconjugate and dynamic nuclear polarization (DNP) metabolic imaging probe composed of hyperpolarized alpha-ketoglutarate (aKG) labeled with carbon C 13, with potential usage in the diagnostic imaging of isocitrate dehydrogenase 1 (IDH1) mutant-expressing cancer cells upon magnetic resonance imaging (MRI). Upon administration, hyperpolarized carbon C 13 aKG (HP 13C-aKG) is taken up by IDH1-expressing cancer cells. In tumors that express wild-type IDH1, only HP 13C-aKG can be detected. In cells that express mutant IDH1, HP 13C-aKG is further metabolized to HP 13C-2-hydroxyglutarate (HP 13C-2-HG) while not in tumor cells expressing wild-type IDH1 or in normal, healthy brain tissue. Upon nuclear magnetic resonance (NMR)-based imaging, HP 13C-aKG is detected in wild-type IDH1-expressing cancer cells, and both HP 13C-aKG and HP 13C-2-HG can be detected in IDH1 mutant-expressing cancer cells though HP 13C-aKG detection decreases in IDH1-mutant-expressing cancer cells over time due to conversion to HP 13C-2-HG. This may aid in the diagnosis of cancers expressing IDH1 and provides mutant IDH1 status of tumor cells.
Synonym:HP 13C-aKG
HP C13-aKG
HP carbon-13 aKG
hyperpolarized 13C-aKG
hyperpolarized carbon-13 alpha-ketoglutarate
Search NCI's Drug Dictionary